{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T23:53:14Z","timestamp":1785541994826,"version":"3.56.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2014,6,7]],"date-time":"2014-06-07T00:00:00Z","timestamp":1402099200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2014,7]]},"DOI":"10.1007\/s40261-014-0204-3","type":"journal-article","created":{"date-parts":[[2014,6,6]],"date-time":"2014-06-06T08:37:57Z","timestamp":1402043877000},"page":"501-511","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Ready Conversion of Patients with Well-Controlled, Moderate to Severe, Chronic Malignant Tumor\u2013related Pain on Other Opioids to Tapentadol Extended Release"],"prefix":"10.1007","volume":"34","author":[{"given":"Keiichiro","family":"Imanaka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yushin","family":"Tominaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mila","family":"Etropolski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Ohashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiichiro","family":"Hirose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taka","family":"Matsumura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,6,7]]},"reference":[{"key":"204_CR1","doi-asserted-by":"crossref","first-page":"135","DOI":"10.2147\/JPR.S6905","volume":"2","author":"J Droney","year":"2009","unstructured":"Droney J, Riley J. Recent advances in the use of opioids for cancer pain. J Pain Res. 2009;2:135\u201355.","journal-title":"J Pain Res."},{"key":"204_CR2","doi-asserted-by":"crossref","first-page":"447","DOI":"10.2147\/tcrm.2006.2.4.447","volume":"2","author":"M Mandala","year":"2006","unstructured":"Mandala M, Moro C, Labianca R, et al. Optimizing use of opiates in the management of cancer pain. Ther Clin Risk Manag. 2006;2:447\u201353.","journal-title":"Ther Clin Risk Manag."},{"key":"204_CR3","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1007\/s00520-011-1281-y","volume":"19","author":"S Mercadante","year":"2011","unstructured":"Mercadante S. Emerging drugs for cancer-related pain. Support Care Cancer. 2011;19:1887\u201393.","journal-title":"Support Care Cancer."},{"key":"204_CR4","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1200\/JCO.2001.19.9.2542","volume":"19","author":"N Cherny","year":"2001","unstructured":"Cherny N, Ripamonti C, Pereira J, et al. Strategies to manage the adverse effects of oral morphine: an evidence-based report. J Clin Oncol. 2001;19:2542\u201354.","journal-title":"J Clin Oncol."},{"key":"204_CR5","doi-asserted-by":"crossref","first-page":"e58","DOI":"10.1016\/S1470-2045(12)70040-2","volume":"13","author":"A Caraceni","year":"2012","unstructured":"Caraceni A, Hanks G, Kaasa S, et al. Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. Lancet Oncol. 2012;13:e58\u201368.","journal-title":"Lancet Oncol."},{"key":"204_CR6","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.ctrv.2006.03.001","volume":"32","author":"S Mercadante","year":"2006","unstructured":"Mercadante S, Bruera E. Opioid switching: a systematic and critical review. Cancer Treat Rev. 2006;32:304\u201315.","journal-title":"Cancer Treat Rev."},{"key":"204_CR7","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1093\/jjco\/hyt099","volume":"43","author":"T Yamaguchi","year":"2013","unstructured":"Yamaguchi T, Shima Y, Morita T, et al. Clinical guideline for pharmacological management of cancer pain: the Japanese Society of Palliative Medicine recommendations. Jpn J Clin Oncol. 2013;43:896\u2013909.","journal-title":"Jpn J Clin Oncol."},{"key":"204_CR8","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1093\/jjco\/hyn010","volume":"38","author":"M Narabayashi","year":"2008","unstructured":"Narabayashi M, Saijo Y, Takenoshita S, et al. Opioid rotation from oral morphine to oral oxycodone in cancer patients with intolerable adverse effects: an open-label trial. Jpn J Clin Oncol. 2008;38:296\u2013304.","journal-title":"Jpn J Clin Oncol."},{"key":"204_CR9","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1177\/1049909112470020","volume":"30","author":"O Takakuwa","year":"2013","unstructured":"Takakuwa O, Oguri T, Maeno K, et al. Analgesic effect of switching from oral opioids to a once-a-day fentanyl citrate transdermal patch in patients with lung cancer. Am J Hosp Palliat Care. 2013;30:726\u20139.","journal-title":"Am J Hosp Palliat Care."},{"key":"204_CR10","first-page":"1545","volume":"55","author":"M Tani","year":"2008","unstructured":"Tani M, Fuku A, Terashita S, et al. Early conversion from oral morphine to transdermal fentanyl in patients with cancer pain. Hepatogastroenterology. 2008;55:1545\u20138.","journal-title":"Hepatogastroenterology."},{"key":"204_CR11","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1358\/dof.2006.031.12.1047744","volume":"31","author":"TM Tzschentke","year":"2006","unstructured":"Tzschentke TM, De Vry J, Terlinden R, et al. Tapentadol hydrochloride. Analgesic, mu-opioid receptor agonist, noradrenaline reuptake inhibitor. Drugs Future. 2006;31:1053\u201361.","journal-title":"Drugs Future."},{"key":"204_CR12","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1124\/jpet.107.126052","volume":"323","author":"TM Tzschentke","year":"2007","unstructured":"Tzschentke TM, Christoph T, K\u00f6gel B, et al. (-)-(1R,2R)-3-(3-Dimethylamino-1-ethyl-2-methyl-propyl)-phenol hydrochloride (tapentadol HCl): a novel \u03bc-opioid receptor agonist\/norepinephrine reuptake inhibitor with broad-spectrum analgesic properties. J Pharmacol Exp Ther. 2007;323:265\u201376.","journal-title":"J Pharmacol Exp Ther."},{"key":"204_CR13","doi-asserted-by":"crossref","first-page":"489","DOI":"10.2165\/11533440-000000000-00000","volume":"30","author":"M Afilalo","year":"2010","unstructured":"Afilalo M, Etropolski MS, Kuperwasser B, et al. Efficacy and safety of tapentadol extended release compared with oxycodone controlled release for the management of moderate to severe chronic pain related to osteoarthritis of the knee: a randomized, double-blind, placebo- and active-controlled phase III study. Clin Drug Investig. 2010;30:489\u2013505.","journal-title":"Clin Drug Investig."},{"key":"204_CR14","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1517\/14656566.2010.497720","volume":"11","author":"R Buynak","year":"2010","unstructured":"Buynak R, Shapiro DY, Okamoto A, et al. Efficacy and safety of tapentadol extended release for the management of chronic low back pain: results of a prospective, randomized, double-blind, placebo- and active-controlled phase III study. Expert Opin Pharmacother. 2010;11:1787\u2013804.","journal-title":"Expert Opin Pharmacother."},{"key":"204_CR15","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s12325-010-0036-3","volume":"27","author":"B Lange","year":"2010","unstructured":"Lange B, Kuperwasser B, Okamoto A, et al. Efficacy and safety of tapentadol prolonged release for chronic osteoarthritis pain and low back pain. Adv Ther. 2010;27:381\u201399.","journal-title":"Adv Ther."},{"key":"204_CR16","unstructured":"Kress HG, Koch ED, Hosturski H, et al. Efficacy and safety of oral tapentadol extended release (ER) for the management of moderate to severe, chronic malignant tumor-related pain [abstract no. A20]. American Society of Regional Anesthesia and Pain Medicine (ASRA) 11th Annual Pain Medicine Meeting; 12\u201315 Nov 2012; Miami."},{"key":"204_CR17","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1185\/03007995.2013.791617","volume":"29","author":"S Mercadante","year":"2013","unstructured":"Mercadante S, Porzio G, Aielli F, et al. Opioid switching from and to tapentadol extended release in cancer patients: conversion ratio with other opioids. Curr Med Res Opin. 2013;29:661\u20136.","journal-title":"Curr Med Res Opin."},{"key":"204_CR18","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1185\/03007995.2013.831816","volume":"29","author":"K Imanaka","year":"2013","unstructured":"Imanaka K, Tominaga Y, Etropolski M, et al. Efficacy and safety of oral tapentadol extended release in Japanese and Korean patients with moderate to severe, chronic malignant tumor-related pain. Curr Med Res Opin. 2013;29:1399\u2013409.","journal-title":"Curr Med Res Opin."},{"key":"204_CR19","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1185\/03007995.2012.739151","volume":"28","author":"S Mercadante","year":"2012","unstructured":"Mercadante S, Porzio G, Ferrera P, et al. Tapentadol in cancer pain management: a prospective open-label study. Curr Med Res Opin. 2012;28:1775\u20139.","journal-title":"Curr Med Res Opin."},{"key":"204_CR20","unstructured":"Schwenke KM, Litzenburger BC. Tapentadol PR in the treatment of cancer pain in clinical practice: first data [poster]. The International Association for the Study of Pain (IASP) 14th World Congress on Pain; 27\u201331 Aug 2012; Milan."},{"key":"204_CR21","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s12325-013-0015-6","volume":"30","author":"R G\u00e1lvez","year":"2013","unstructured":"G\u00e1lvez R, Sch\u00e4fer M, Hans G, et al. Tapentadol prolonged release versus strong opioids for severe, chronic low back pain: results of an open-label, phase IIIb study. Adv Ther. 2013;30:229\u201359.","journal-title":"Adv Ther."},{"key":"204_CR22","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1007\/s40261-013-0102-0","volume":"33","author":"I Steigerwald","year":"2013","unstructured":"Steigerwald I, Schenk M, Lahne U, et al. Effectiveness and tolerability of tapentadol prolonged release compared with prior opioid therapy for the management of severe, chronic osteoarthritis pain. Clin Drug Investig. 2013;33:607\u201319.","journal-title":"Clin Drug Investig."},{"key":"204_CR23","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/0304-3959(95)00180-8","volume":"64","author":"B Donner","year":"1996","unstructured":"Donner B, Zenz M, Tryba M, et al. Direct conversion from oral morphine to transdermal fentanyl: a multicenter study in patients with cancer pain. Pain. 1996;64:527\u201334.","journal-title":"Pain."},{"key":"204_CR24","unstructured":"OXYCONTIN\u00ae (oxycodone hydrochloride controlled-release) tablets [package insert]. Stamford: Purdue Pharma L.P.; 2010."},{"key":"204_CR25","first-page":"281","volume":"21","author":"T Fumikazu","year":"2005","unstructured":"Fumikazu T, Hideo Y, Yasuo K, et al. Clinical evaluation of cancer patients who switched from controlled-release morphine sulfate tablets to S-8117 (controlled release oxycodone hydrochloride tablets)\u2014phase II clinical study. J Clin Ther Med. 2005;21:281\u201393.","journal-title":"J Clin Ther Med."},{"key":"204_CR26","volume-title":"Clinical guidelines for cancer pain management","author":"Japanese Society for Palliative Medicine","year":"2005","unstructured":"Japanese Society for Palliative Medicine. Clinical guidelines for cancer pain management. Tokyo: Kanehara and Co., Ltd; 2005."},{"key":"204_CR27","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.pain.2004.09.012","volume":"113","author":"RH Dworkin","year":"2005","unstructured":"Dworkin RH, Turk DC, Farrar JT, et al. Core outcome measures for chronic pain clinical trials: IMMPACT recommendations. Pain. 2005;113:9\u201319.","journal-title":"Pain."},{"key":"204_CR28","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0304-3959(01)00349-9","volume":"94","author":"JT Farrar","year":"2001","unstructured":"Farrar JT, Young JP Jr, LaMoreaux L, et al. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain. 2001;94:149\u201358.","journal-title":"Pain."},{"key":"204_CR29","first-page":"147","volume":"60","author":"K Hanaoka","year":"2011","unstructured":"Hanaoka K, Yoshimura T, Tomioka T, et al. Clinical study of one-day fentanyl patch in patients with cancer pain\u2013evaluation of the efficacy and safety in relation to treatment switch from opioid analgesic therapy. Jpn J Anesthesiol (Masui). 2011;60:147\u201356.","journal-title":"Jpn J Anesthesiol (Masui)."},{"key":"204_CR30","doi-asserted-by":"crossref","unstructured":"Wiffen PJ, McQuay HJ. Oral morphine for cancer pain. Cochrane Database Syst Rev. 2007;(4):CD003868.","DOI":"10.1002\/14651858.CD003868.pub2"},{"key":"204_CR31","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1111\/j.1533-2500.2010.00397.x","volume":"10","author":"JE Wild","year":"2010","unstructured":"Wild JE, Grond S, Kuperwasser B, et al. Long-term safety and tolerability of tapentadol extended release for the management of chronic low back pain or osteoarthritis pain. Pain Pract. 2010;10:416\u201327.","journal-title":"Pain Pract."},{"key":"204_CR32","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1185\/03007990902952825","volume":"25","author":"S Daniels","year":"2009","unstructured":"Daniels S, Casson E, Stegmann JU, et al. A randomized, double-blind, placebo-controlled phase 3 study of the relative efficacy and tolerability of tapentadol IR and oxycodone IR for acute pain. Curr Med Res Opin. 2009;25:1551\u201361.","journal-title":"Curr Med Res Opin."},{"key":"204_CR33","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.clinthera.2009.02.009","volume":"31","author":"C Hartrick","year":"2009","unstructured":"Hartrick C, Van Hove I, Stegmann J-U, et al. Efficacy and tolerability of tapentadol immediate release and oxycodone HCl immediate release in patients awaiting primary joint replacement surgery for end-stage joint disease: a 10-day, phase III, randomized, double-blind, active- and placebo-controlled study. Clin Ther. 2009;31:260\u201371.","journal-title":"Clin Ther."},{"key":"204_CR34","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1111\/j.1742-1241.2007.01415.x","volume":"61","author":"SJ Panchal","year":"2007","unstructured":"Panchal SJ, Muller-Schwefe P, Wurzelmann JI. Opioid-induced bowel dysfunction: prevalence, pathophysiology and burden. Int J Clin Pract. 2007;61:1181\u20137.","journal-title":"Int J Clin Pract."},{"key":"204_CR35","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1080\/15360280903098440","volume":"23","author":"SD Candrilli","year":"2009","unstructured":"Candrilli SD, Davis KL, Iyer S. Impact of constipation on opioid use patterns, health care resource utilization, and costs in cancer patients on opioid therapy. J Pain Palliat Care Pharmacother. 2009;23:231\u201341.","journal-title":"J Pain Palliat Care Pharmacother."},{"key":"204_CR36","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1002\/(SICI)1097-0142(19991101)86:9<1856::AID-CNCR30>3.0.CO;2-G","volume":"86","author":"S Mercadante","year":"1999","unstructured":"Mercadante S. Opioid rotation for cancer pain: rationale and clinical aspects. Cancer. 1999;86:1856\u201366.","journal-title":"Cancer."},{"key":"204_CR37","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1185\/03007995.2012.679254","volume":"28","author":"I Steigerwald","year":"2012","unstructured":"Steigerwald I, Muller M, Davies A, et al. Effectiveness and safety of tapentadol prolonged release for severe, chronic low back pain with or without a neuropathic pain component: results of an open-label, phase 3b study. Curr Med Res Opin. 2012;28:911\u201336.","journal-title":"Curr Med Res Opin."},{"key":"204_CR38","doi-asserted-by":"crossref","unstructured":"Kosugi T, Hamada S, Takigawa C, et al. A randomized, double-blind, placebo-controlled study of fentanyl buccal tablets for breakthrough pain: efficacy and safety in japanese cancer patients. J Pain Symptom Manage. Epub 2013 Oct 5.","DOI":"10.1016\/j.jpainsymman.2013.07.006"},{"key":"204_CR39","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1093\/jjco\/hyh104","volume":"34","author":"W Koizumi","year":"2004","unstructured":"Koizumi W, Toma H, Watanabe K, et al. Efficacy and tolerability of cancer pain management with controlled-release oxycodone tablets in opioid-naive cancer pain patients, starting with 5\u00a0mg tablets. Jpn J Clin Oncol. 2004;34:608\u201314.","journal-title":"Jpn J Clin Oncol."},{"key":"204_CR40","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.jpainsymman.2013.03.015","volume":"47","author":"B Duthey","year":"2014","unstructured":"Duthey B, Scholten W. Adequacy of opioid analgesic consumption at country, global, and regional levels in 2010, its relationship with development level, and changes compared with 2006. J Pain Symptom Manage. 2014;47:283\u201397.","journal-title":"J Pain Symptom Manage."}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40261-014-0204-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-014-0204-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-014-0204-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,6]],"date-time":"2022-04-06T07:33:37Z","timestamp":1649230417000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40261-014-0204-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6,7]]},"references-count":40,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2014,7]]}},"alternative-id":["204"],"URL":"https:\/\/doi.org\/10.1007\/s40261-014-0204-3","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,6,7]]}}}